$162.00
+1.95 (+1.22%)
At Close: May 23, 2025
Ascendis Pharma A/S Earnings Calls
Q1 2025
Missed
-$1.66 (-6.41%)
Release date | May 01, 2025 |
EPS estimate | -$1.56 |
EPS actual | -$1.66 |
EPS Surprise | -6.41% |
Revenue estimate | 153.477M |
Revenue actual | 110.671M |
Revenue Surprise | -27.89% |
Q4 2024
Beat
-$0.680 (43.33%)
Release date | Feb 12, 2025 |
EPS estimate | -$1.20 |
EPS actual | -$0.680 |
EPS Surprise | 43.33% |
Revenue estimate | 125.416M |
Revenue actual | 180.088M |
Revenue Surprise | 43.59% |
Q3 2024
Missed
-$1.89 (-26.85%)
Release date | Nov 14, 2024 |
EPS estimate | -$1.49 |
EPS actual | -$1.89 |
EPS Surprise | -26.85% |
Revenue estimate | 70.312M |
Revenue actual | 363.641M |
Revenue Surprise | 417.18% |
Q2 2024
Missed
-$2.05 (-33.12%)
Release date | Sep 03, 2024 |
EPS estimate | -$1.54 |
EPS actual | -$2.05 |
EPS Surprise | -33.12% |
Revenue estimate | 37.576M |
Revenue actual | 38.706M |
Revenue Surprise | 3.01% |
Last 4 Quarters for Ascendis Pharma A/S
Below you can see how ASND performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Missed
Release date | Sep 03, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $134.68 |
EPS estimate | -$1.54 |
EPS actual | -$2.05 |
EPS surprise | -33.12% |
Date | Price |
---|---|
Aug 27, 2024 | $138.79 |
Aug 28, 2024 | $138.91 |
Aug 29, 2024 | $137.94 |
Aug 30, 2024 | $138.45 |
Sep 03, 2024 | $134.68 |
Sep 04, 2024 | $119.50 |
Sep 05, 2024 | $119.00 |
Sep 06, 2024 | $119.15 |
Sep 09, 2024 | $116.84 |
4 days before | -2.96% |
4 days after | -13.25% |
On release day | -11.27% |
Change in period | -15.82% |
Q3 2024
Missed
Release date | Nov 14, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $124.28 |
EPS estimate | -$1.49 |
EPS actual | -$1.89 |
EPS surprise | -26.85% |
Date | Price |
---|---|
Nov 08, 2024 | $124.33 |
Nov 11, 2024 | $128.40 |
Nov 12, 2024 | $127.67 |
Nov 13, 2024 | $126.03 |
Nov 14, 2024 | $124.28 |
Nov 15, 2024 | $126.51 |
Nov 18, 2024 | $122.00 |
Nov 19, 2024 | $124.44 |
Nov 20, 2024 | $124.38 |
4 days before | -0.0402% |
4 days after | 0.0805% |
On release day | 1.79% |
Change in period | 0.0402% |
Q4 2024
Beat
Release date | Feb 12, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $126.14 |
EPS estimate | -$1.20 |
EPS actual | -$0.680 |
EPS surprise | 43.33% |
Date | Price |
---|---|
Feb 06, 2025 | $125.02 |
Feb 07, 2025 | $120.87 |
Feb 10, 2025 | $119.47 |
Feb 11, 2025 | $119.51 |
Feb 12, 2025 | $126.14 |
Feb 13, 2025 | $142.49 |
Feb 14, 2025 | $144.08 |
Feb 18, 2025 | $156.19 |
Feb 19, 2025 | $155.11 |
4 days before | 0.90% |
4 days after | 22.97% |
On release day | 12.96% |
Change in period | 24.07% |
Q1 2025
Missed
Release date | May 01, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $167.47 |
EPS estimate | -$1.56 |
EPS actual | -$1.66 |
EPS surprise | -6.41% |
Date | Price |
---|---|
Apr 25, 2025 | $164.15 |
Apr 28, 2025 | $164.88 |
Apr 29, 2025 | $166.58 |
Apr 30, 2025 | $170.44 |
May 01, 2025 | $167.47 |
May 02, 2025 | $172.06 |
May 05, 2025 | $170.74 |
May 06, 2025 | $162.84 |
May 07, 2025 | $160.99 |
4 days before | 2.02% |
4 days after | -3.87% |
On release day | 2.74% |
Change in period | -1.93% |
Ascendis Pharma A/S Earnings Call Transcript Summary of Q1 2025
Ascendis Pharma First Quarter 2025 Earnings Call Summary for Investors
Key Highlights:
- Financial Performance:
- Total revenue for Q1 2025 was €101 million, up significantly from previous quarters, driven mainly by strong sales of YORVIPATH and SKYTROFA.
- YORVIPATH generated €44.7 million, a substantial increase from €13.6 million in Q4 2024, indicating robust U.S. launch demand.
- SKYTROFA's revenue was €51.3 million, with a stable market share but affected by seasonal dynamics in the U.S.
- Product Updates:
- YORVIPATH:
- Approved for hypoparathyroidism treatment in adults, with over 1,750 patients prescribed in Q1 from 1,000+ healthcare providers.
- Growth expected as reimbursement becomes available in additional European countries later in 2025.
- Positioned to address a significant patient population (estimated 70,000-90,000 in the U.S. with chronic hypoparathyroidism).
- SKYTROFA:
- Leading position in the long-acting growth hormone market with potential for label expansion in adult growth hormone deficiency (PDUFA date: July 27, 2025).
- Ongoing basket trial for various indications, including short stature and Turner syndrome.
- TransCon CNP:
- In clinical trials for treating achondroplasia, with promising data on improving growth and quality of life.
- NDA filed with the FDA and a European submission expected in Q3 2025.
- YORVIPATH:
- Market Dynamics:
- Reimbursement & Payer Engagement:
- Positive trends in reimbursement approvals for YORVIPATH; expectation that around 17-18% of patients will secure reimbursement once the launch stabilizes.
- Ascendis is confident in effectively navigating payer complexities, leveraging experience from SKYTROFA's launch.
- Reimbursement & Payer Engagement:
- Future Outlook:
- 2025 is poised to be transformative for Ascendis, with expectations of substantial revenue growth driven by YORVIPATH and SKYTROFA.
- Continued focus on addressing unmet medical needs, developing combination therapies (CNP and growth hormones), and expanding indications to maximize patient outcomes.
- Encouraged by high patient adherence rates and positive early launch dynamics.
- Cash Position:
- Ended Q1 2025 with cash and cash equivalents of €518 million, providing a solid financial foundation for ongoing operations and investments in growth.
Investment Considerations:
- Ascendis Pharma is positioned for growth with its current product portfolio, promising pipeline, and effective launch strategies.
- Investors should monitor upcoming regulatory approvals for SKYTROFA and TransCon CNP, as well as the market adoption rates of YORVIPATH.
- The evolving reimbursement landscape and competition dynamics (notably from other products targeting similar patient populations) will be crucial for revenue forecasts.
Conclusion:
Ascendis Pharma demonstrates strong operational execution and a strategic focus on addressing significant unmet medical needs, making it a company to watch in the biopharma space going forward.
Ascendis Pharma A/S Earnings History
Earnings Calendar
FAQ
When is the earnings report for ASND?
Ascendis Pharma A/S (ASND) has scheduled its earnings report for Sep 02, 2025 after the markets close.
What is the ASND price-to-earnings (P/E) ratio?
ASND P/E ratio as of May 23, 2025 (TTM) is -25.03.
What is the ASND EPS forecast?
The forecasted EPS (Earnings Per Share) for Ascendis Pharma A/S (ASND) for the first fiscal quarter 2025 is -$1.41.
What are Ascendis Pharma A/S's retained earnings?
On its balance sheet, Ascendis Pharma A/S reported retained earnings of $110.67 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.